nodes	percent_of_prediction	percent_of_DWPC	metapath
Raloxifene—ESR2—urinary bladder cancer	0.354	0.619	CbGaD
Raloxifene—ESR1—urinary bladder cancer	0.218	0.381	CbGaD
Raloxifene—CYP2B6—Thiotepa—urinary bladder cancer	0.0716	0.304	CbGbCtD
Raloxifene—AOX1—Methotrexate—urinary bladder cancer	0.0668	0.283	CbGbCtD
Raloxifene—CYP3A4—Thiotepa—urinary bladder cancer	0.022	0.0933	CbGbCtD
Raloxifene—CYP2B6—Cisplatin—urinary bladder cancer	0.0198	0.0838	CbGbCtD
Raloxifene—CYP2C8—Fluorouracil—urinary bladder cancer	0.0176	0.0747	CbGbCtD
Raloxifene—CYP2C8—Etoposide—urinary bladder cancer	0.0147	0.0624	CbGbCtD
Raloxifene—CYP2B6—Doxorubicin—urinary bladder cancer	0.0132	0.0562	CbGbCtD
Raloxifene—CYP3A4—Etoposide—urinary bladder cancer	0.00596	0.0253	CbGbCtD
Raloxifene—CYP3A4—Doxorubicin—urinary bladder cancer	0.00407	0.0173	CbGbCtD
Raloxifene—EBP—female reproductive system—urinary bladder cancer	0.00232	0.0679	CbGeAlD
Raloxifene—CYP3A4—urine—urinary bladder cancer	0.00157	0.0461	CbGeAlD
Raloxifene—ESR2—prostate gland—urinary bladder cancer	0.00148	0.0433	CbGeAlD
Raloxifene—AOX1—prostate gland—urinary bladder cancer	0.00142	0.0417	CbGeAlD
Raloxifene—AOX1—seminal vesicle—urinary bladder cancer	0.0012	0.0353	CbGeAlD
Raloxifene—CYP19A1—prostate gland—urinary bladder cancer	0.00116	0.0341	CbGeAlD
Raloxifene—SIGMAR1—prostate gland—urinary bladder cancer	0.00114	0.0336	CbGeAlD
Raloxifene—ESR2—epithelium—urinary bladder cancer	0.00109	0.0318	CbGeAlD
Raloxifene—EBP—Azacitidine—Gemcitabine—urinary bladder cancer	0.00105	1	CbGdCrCtD
Raloxifene—ESR2—smooth muscle tissue—urinary bladder cancer	0.00105	0.0307	CbGeAlD
Raloxifene—ESR1—prostate gland—urinary bladder cancer	0.00101	0.0297	CbGeAlD
Raloxifene—ESR2—renal system—urinary bladder cancer	0.00101	0.0295	CbGeAlD
Raloxifene—AOX1—renal system—urinary bladder cancer	0.000969	0.0284	CbGeAlD
Raloxifene—SIGMAR1—seminal vesicle—urinary bladder cancer	0.000968	0.0284	CbGeAlD
Raloxifene—AOX1—urethra—urinary bladder cancer	0.000952	0.0279	CbGeAlD
Raloxifene—SIGMAR1—smooth muscle tissue—urinary bladder cancer	0.00081	0.0238	CbGeAlD
Raloxifene—HTR2B—smooth muscle tissue—urinary bladder cancer	0.000809	0.0237	CbGeAlD
Raloxifene—ESR2—female reproductive system—urinary bladder cancer	0.000806	0.0237	CbGeAlD
Raloxifene—AOX1—female reproductive system—urinary bladder cancer	0.000776	0.0228	CbGeAlD
Raloxifene—SIGMAR1—urethra—urinary bladder cancer	0.000766	0.0225	CbGeAlD
Raloxifene—ESR1—epithelium—urinary bladder cancer	0.000743	0.0218	CbGeAlD
Raloxifene—ESR2—vagina—urinary bladder cancer	0.000729	0.0214	CbGeAlD
Raloxifene—ESR1—smooth muscle tissue—urinary bladder cancer	0.000716	0.021	CbGeAlD
Raloxifene—AOX1—vagina—urinary bladder cancer	0.000702	0.0206	CbGeAlD
Raloxifene—ESR1—renal system—urinary bladder cancer	0.00069	0.0202	CbGeAlD
Raloxifene—CYP19A1—female reproductive system—urinary bladder cancer	0.000635	0.0186	CbGeAlD
Raloxifene—HTR2B—female reproductive system—urinary bladder cancer	0.000623	0.0183	CbGeAlD
Raloxifene—CYP2C8—renal system—urinary bladder cancer	0.000568	0.0167	CbGeAlD
Raloxifene—SIGMAR1—vagina—urinary bladder cancer	0.000565	0.0166	CbGeAlD
Raloxifene—HTR2B—vagina—urinary bladder cancer	0.000564	0.0165	CbGeAlD
Raloxifene—ESR1—female reproductive system—urinary bladder cancer	0.000552	0.0162	CbGeAlD
Raloxifene—CYP2B6—renal system—urinary bladder cancer	0.00051	0.0149	CbGeAlD
Raloxifene—ESR1—vagina—urinary bladder cancer	0.000499	0.0147	CbGeAlD
Raloxifene—ESR2—lymph node—urinary bladder cancer	0.000472	0.0138	CbGeAlD
Raloxifene—CYP2C8—female reproductive system—urinary bladder cancer	0.000455	0.0133	CbGeAlD
Raloxifene—AOX1—lymph node—urinary bladder cancer	0.000454	0.0133	CbGeAlD
Raloxifene—CYP2C8—vagina—urinary bladder cancer	0.000411	0.0121	CbGeAlD
Raloxifene—CYP2B6—female reproductive system—urinary bladder cancer	0.000408	0.012	CbGeAlD
Raloxifene—CYP3A4—renal system—urinary bladder cancer	0.000385	0.0113	CbGeAlD
Raloxifene—CYP19A1—lymph node—urinary bladder cancer	0.000372	0.0109	CbGeAlD
Raloxifene—CYP2B6—vagina—urinary bladder cancer	0.000369	0.0108	CbGeAlD
Raloxifene—SIGMAR1—lymph node—urinary bladder cancer	0.000365	0.0107	CbGeAlD
Raloxifene—HTR2B—lymph node—urinary bladder cancer	0.000365	0.0107	CbGeAlD
Raloxifene—ESR1—lymph node—urinary bladder cancer	0.000323	0.00948	CbGeAlD
Raloxifene—CYP3A4—female reproductive system—urinary bladder cancer	0.000308	0.00904	CbGeAlD
Raloxifene—Nervous system disorder—Thiotepa—urinary bladder cancer	0.000208	0.00207	CcSEcCtD
Raloxifene—Thrombocytopenia—Thiotepa—urinary bladder cancer	0.000207	0.00207	CcSEcCtD
Raloxifene—Skin disorder—Thiotepa—urinary bladder cancer	0.000206	0.00205	CcSEcCtD
Raloxifene—Cramps of lower extremities—Doxorubicin—urinary bladder cancer	0.000203	0.00203	CcSEcCtD
Raloxifene—Flatulence—Cisplatin—urinary bladder cancer	0.000201	0.002	CcSEcCtD
Raloxifene—Bladder pain—Doxorubicin—urinary bladder cancer	0.0002	0.00199	CcSEcCtD
Raloxifene—Diabetes mellitus—Epirubicin—urinary bladder cancer	0.0002	0.00199	CcSEcCtD
Raloxifene—Flushing—Etoposide—urinary bladder cancer	0.000199	0.00198	CcSEcCtD
Raloxifene—Cardiac disorder—Etoposide—urinary bladder cancer	0.000199	0.00198	CcSEcCtD
Raloxifene—Muscle spasms—Cisplatin—urinary bladder cancer	0.000196	0.00195	CcSEcCtD
Raloxifene—Angiopathy—Etoposide—urinary bladder cancer	0.000194	0.00194	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Thiotepa—urinary bladder cancer	0.000193	0.00192	CcSEcCtD
Raloxifene—Cough—Gemcitabine—urinary bladder cancer	0.000191	0.0019	CcSEcCtD
Raloxifene—Cerebrovascular accident—Methotrexate—urinary bladder cancer	0.000189	0.00189	CcSEcCtD
Raloxifene—Dyspepsia—Thiotepa—urinary bladder cancer	0.000186	0.00186	CcSEcCtD
Raloxifene—Chest pain—Gemcitabine—urinary bladder cancer	0.000186	0.00185	CcSEcCtD
Raloxifene—Arthralgia—Gemcitabine—urinary bladder cancer	0.000186	0.00185	CcSEcCtD
Raloxifene—Myalgia—Gemcitabine—urinary bladder cancer	0.000186	0.00185	CcSEcCtD
Raloxifene—Hot flush—Epirubicin—urinary bladder cancer	0.000186	0.00185	CcSEcCtD
Raloxifene—Diabetes mellitus—Doxorubicin—urinary bladder cancer	0.000185	0.00184	CcSEcCtD
Raloxifene—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—urinary bladder cancer	0.000185	0.00184	CcSEcCtD
Raloxifene—Menopausal symptoms—Epirubicin—urinary bladder cancer	0.000184	0.00183	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Thiotepa—urinary bladder cancer	0.000183	0.00182	CcSEcCtD
Raloxifene—Myalgia—Fluorouracil—urinary bladder cancer	0.000183	0.00182	CcSEcCtD
Raloxifene—Chest pain—Fluorouracil—urinary bladder cancer	0.000183	0.00182	CcSEcCtD
Raloxifene—Pain—Thiotepa—urinary bladder cancer	0.000181	0.00181	CcSEcCtD
Raloxifene—Muscle spasms—Etoposide—urinary bladder cancer	0.000179	0.00179	CcSEcCtD
Raloxifene—Cerebrovascular accident—Epirubicin—urinary bladder cancer	0.000177	0.00176	CcSEcCtD
Raloxifene—Infection—Gemcitabine—urinary bladder cancer	0.000177	0.00176	CcSEcCtD
Raloxifene—Nervous system disorder—Gemcitabine—urinary bladder cancer	0.000175	0.00174	CcSEcCtD
Raloxifene—Thrombocytopenia—Gemcitabine—urinary bladder cancer	0.000174	0.00174	CcSEcCtD
Raloxifene—Infection—Fluorouracil—urinary bladder cancer	0.000174	0.00173	CcSEcCtD
Raloxifene—Myalgia—Cisplatin—urinary bladder cancer	0.000173	0.00173	CcSEcCtD
Raloxifene—Gastrointestinal pain—Thiotepa—urinary bladder cancer	0.000173	0.00173	CcSEcCtD
Raloxifene—Skin disorder—Gemcitabine—urinary bladder cancer	0.000173	0.00172	CcSEcCtD
Raloxifene—Hyperhidrosis—Gemcitabine—urinary bladder cancer	0.000172	0.00172	CcSEcCtD
Raloxifene—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—urinary bladder cancer	0.000172	0.00171	CcSEcCtD
Raloxifene—Nervous system disorder—Fluorouracil—urinary bladder cancer	0.000172	0.00171	CcSEcCtD
Raloxifene—Hot flush—Doxorubicin—urinary bladder cancer	0.000172	0.00171	CcSEcCtD
Raloxifene—Thrombocytopenia—Fluorouracil—urinary bladder cancer	0.000172	0.00171	CcSEcCtD
Raloxifene—Migraine—Epirubicin—urinary bladder cancer	0.000171	0.0017	CcSEcCtD
Raloxifene—Menopausal symptoms—Doxorubicin—urinary bladder cancer	0.00017	0.0017	CcSEcCtD
Raloxifene—Breast disorder—Methotrexate—urinary bladder cancer	0.000168	0.00167	CcSEcCtD
Raloxifene—Vertigo—Etoposide—urinary bladder cancer	0.000168	0.00167	CcSEcCtD
Raloxifene—Abdominal pain—Thiotepa—urinary bladder cancer	0.000167	0.00167	CcSEcCtD
Raloxifene—Body temperature increased—Thiotepa—urinary bladder cancer	0.000167	0.00167	CcSEcCtD
Raloxifene—Infection—Cisplatin—urinary bladder cancer	0.000165	0.00164	CcSEcCtD
Raloxifene—Loss of consciousness—Etoposide—urinary bladder cancer	0.000164	0.00163	CcSEcCtD
Raloxifene—Cerebrovascular accident—Doxorubicin—urinary bladder cancer	0.000164	0.00163	CcSEcCtD
Raloxifene—Nervous system disorder—Cisplatin—urinary bladder cancer	0.000163	0.00162	CcSEcCtD
Raloxifene—Cough—Etoposide—urinary bladder cancer	0.000163	0.00162	CcSEcCtD
Raloxifene—Thrombocytopenia—Cisplatin—urinary bladder cancer	0.000163	0.00162	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Gemcitabine—urinary bladder cancer	0.000162	0.00162	CcSEcCtD
Raloxifene—Skin disorder—Cisplatin—urinary bladder cancer	0.000161	0.00161	CcSEcCtD
Raloxifene—Insomnia—Gemcitabine—urinary bladder cancer	0.000161	0.00161	CcSEcCtD
Raloxifene—Hyperhidrosis—Cisplatin—urinary bladder cancer	0.000161	0.0016	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Fluorouracil—urinary bladder cancer	0.00016	0.00159	CcSEcCtD
Raloxifene—Chest pain—Etoposide—urinary bladder cancer	0.000159	0.00158	CcSEcCtD
Raloxifene—Insomnia—Fluorouracil—urinary bladder cancer	0.000158	0.00158	CcSEcCtD
Raloxifene—Migraine—Doxorubicin—urinary bladder cancer	0.000158	0.00157	CcSEcCtD
Raloxifene—Unspecified disorder of skin and subcutaneous tissue—Etoposide—urinary bladder cancer	0.000158	0.00157	CcSEcCtD
Raloxifene—Breast disorder—Epirubicin—urinary bladder cancer	0.000157	0.00156	CcSEcCtD
Raloxifene—Aspartate aminotransferase increased—Epirubicin—urinary bladder cancer	0.000156	0.00156	CcSEcCtD
Raloxifene—Dyspepsia—Fluorouracil—urinary bladder cancer	0.000154	0.00154	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.000154	0.00153	CcSEcCtD
Raloxifene—Pain—Gemcitabine—urinary bladder cancer	0.000152	0.00152	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	0.000151	0.00151	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.000151	0.00151	CcSEcCtD
Raloxifene—Infection—Etoposide—urinary bladder cancer	0.000151	0.00151	CcSEcCtD
Raloxifene—Influenza—Epirubicin—urinary bladder cancer	0.00015	0.00149	CcSEcCtD
Raloxifene—Pain—Fluorouracil—urinary bladder cancer	0.00015	0.00149	CcSEcCtD
Raloxifene—Thrombocytopenia—Etoposide—urinary bladder cancer	0.000149	0.00148	CcSEcCtD
Raloxifene—Skin disorder—Etoposide—urinary bladder cancer	0.000148	0.00147	CcSEcCtD
Raloxifene—Hyperhidrosis—Etoposide—urinary bladder cancer	0.000147	0.00147	CcSEcCtD
Raloxifene—Breast disorder—Doxorubicin—urinary bladder cancer	0.000145	0.00145	CcSEcCtD
Raloxifene—Diarrhoea—Thiotepa—urinary bladder cancer	0.000145	0.00144	CcSEcCtD
Raloxifene—Aspartate aminotransferase increased—Doxorubicin—urinary bladder cancer	0.000145	0.00144	CcSEcCtD
Raloxifene—Bronchitis—Epirubicin—urinary bladder cancer	0.000144	0.00144	CcSEcCtD
Raloxifene—Pneumonia—Methotrexate—urinary bladder cancer	0.000144	0.00143	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000143	0.00143	CcSEcCtD
Raloxifene—Depression—Methotrexate—urinary bladder cancer	0.000143	0.00142	CcSEcCtD
Raloxifene—Pain—Cisplatin—urinary bladder cancer	0.000142	0.00142	CcSEcCtD
Raloxifene—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000141	0.0014	CcSEcCtD
Raloxifene—Dizziness—Thiotepa—urinary bladder cancer	0.00014	0.0014	CcSEcCtD
Raloxifene—Conjunctivitis—Methotrexate—urinary bladder cancer	0.000139	0.00138	CcSEcCtD
Raloxifene—Influenza—Doxorubicin—urinary bladder cancer	0.000139	0.00138	CcSEcCtD
Raloxifene—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000139	0.00138	CcSEcCtD
Raloxifene—Sweating—Methotrexate—urinary bladder cancer	0.000137	0.00137	CcSEcCtD
Raloxifene—Weight increased—Epirubicin—urinary bladder cancer	0.000137	0.00136	CcSEcCtD
Raloxifene—Vomiting—Thiotepa—urinary bladder cancer	0.000135	0.00134	CcSEcCtD
Raloxifene—Pneumonia—Epirubicin—urinary bladder cancer	0.000135	0.00134	CcSEcCtD
Raloxifene—Rash—Thiotepa—urinary bladder cancer	0.000134	0.00133	CcSEcCtD
Raloxifene—Bronchitis—Doxorubicin—urinary bladder cancer	0.000133	0.00133	CcSEcCtD
Raloxifene—Dermatitis—Thiotepa—urinary bladder cancer	0.000133	0.00133	CcSEcCtD
Raloxifene—Headache—Thiotepa—urinary bladder cancer	0.000133	0.00132	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000131	0.00131	CcSEcCtD
Raloxifene—Body temperature increased—Cisplatin—urinary bladder cancer	0.000131	0.00131	CcSEcCtD
Raloxifene—Pain—Etoposide—urinary bladder cancer	0.00013	0.0013	CcSEcCtD
Raloxifene—Urinary tract infection—Epirubicin—urinary bladder cancer	0.00013	0.0013	CcSEcCtD
Raloxifene—Conjunctivitis—Epirubicin—urinary bladder cancer	0.00013	0.0013	CcSEcCtD
Raloxifene—Sweating—Epirubicin—urinary bladder cancer	0.000128	0.00128	CcSEcCtD
Raloxifene—Pharyngitis—Methotrexate—urinary bladder cancer	0.000127	0.00127	CcSEcCtD
Raloxifene—Urinary tract disorder—Methotrexate—urinary bladder cancer	0.000127	0.00126	CcSEcCtD
Raloxifene—Weight increased—Doxorubicin—urinary bladder cancer	0.000126	0.00126	CcSEcCtD
Raloxifene—Nausea—Thiotepa—urinary bladder cancer	0.000126	0.00125	CcSEcCtD
Raloxifene—Urethral disorder—Methotrexate—urinary bladder cancer	0.000126	0.00125	CcSEcCtD
Raloxifene—Sinusitis—Epirubicin—urinary bladder cancer	0.000125	0.00125	CcSEcCtD
Raloxifene—Pneumonia—Doxorubicin—urinary bladder cancer	0.000124	0.00124	CcSEcCtD
Raloxifene—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000124	0.00124	CcSEcCtD
Raloxifene—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000122	0.00121	CcSEcCtD
Raloxifene—Rhinitis—Epirubicin—urinary bladder cancer	0.00012	0.0012	CcSEcCtD
Raloxifene—Body temperature increased—Etoposide—urinary bladder cancer	0.00012	0.0012	CcSEcCtD
Raloxifene—Abdominal pain—Etoposide—urinary bladder cancer	0.00012	0.0012	CcSEcCtD
Raloxifene—Conjunctivitis—Doxorubicin—urinary bladder cancer	0.00012	0.0012	CcSEcCtD
Raloxifene—Urinary tract infection—Doxorubicin—urinary bladder cancer	0.00012	0.0012	CcSEcCtD
Raloxifene—Diarrhoea—Fluorouracil—urinary bladder cancer	0.00012	0.00119	CcSEcCtD
Raloxifene—Hypoaesthesia—Epirubicin—urinary bladder cancer	0.000119	0.00119	CcSEcCtD
Raloxifene—Pharyngitis—Epirubicin—urinary bladder cancer	0.000119	0.00119	CcSEcCtD
Raloxifene—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000119	0.00119	CcSEcCtD
Raloxifene—Sweating—Doxorubicin—urinary bladder cancer	0.000119	0.00118	CcSEcCtD
Raloxifene—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000119	0.00118	CcSEcCtD
Raloxifene—Oedema peripheral—Epirubicin—urinary bladder cancer	0.000118	0.00118	CcSEcCtD
Raloxifene—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000118	0.00118	CcSEcCtD
Raloxifene—Urethral disorder—Epirubicin—urinary bladder cancer	0.000118	0.00117	CcSEcCtD
Raloxifene—Angiopathy—Methotrexate—urinary bladder cancer	0.000116	0.00116	CcSEcCtD
Raloxifene—Sinusitis—Doxorubicin—urinary bladder cancer	0.000116	0.00116	CcSEcCtD
Raloxifene—Dizziness—Fluorouracil—urinary bladder cancer	0.000116	0.00115	CcSEcCtD
Raloxifene—Diarrhoea—Cisplatin—urinary bladder cancer	0.000114	0.00113	CcSEcCtD
Raloxifene—Vomiting—Gemcitabine—urinary bladder cancer	0.000113	0.00113	CcSEcCtD
Raloxifene—Rash—Gemcitabine—urinary bladder cancer	0.000112	0.00112	CcSEcCtD
Raloxifene—Dermatitis—Gemcitabine—urinary bladder cancer	0.000112	0.00112	CcSEcCtD
Raloxifene—Headache—Gemcitabine—urinary bladder cancer	0.000112	0.00111	CcSEcCtD
Raloxifene—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000111	0.00111	CcSEcCtD
Raloxifene—Flushing—Epirubicin—urinary bladder cancer	0.000111	0.00111	CcSEcCtD
Raloxifene—Vomiting—Fluorouracil—urinary bladder cancer	0.000111	0.00111	CcSEcCtD
Raloxifene—Rhinitis—Doxorubicin—urinary bladder cancer	0.000111	0.00111	CcSEcCtD
Raloxifene—Hypoaesthesia—Doxorubicin—urinary bladder cancer	0.000111	0.0011	CcSEcCtD
Raloxifene—Rash—Fluorouracil—urinary bladder cancer	0.00011	0.0011	CcSEcCtD
Raloxifene—Dermatitis—Fluorouracil—urinary bladder cancer	0.00011	0.0011	CcSEcCtD
Raloxifene—Pharyngitis—Doxorubicin—urinary bladder cancer	0.00011	0.0011	CcSEcCtD
Raloxifene—Headache—Fluorouracil—urinary bladder cancer	0.00011	0.00109	CcSEcCtD
Raloxifene—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.00011	0.00109	CcSEcCtD
Raloxifene—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.000109	0.00109	CcSEcCtD
Raloxifene—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000109	0.00109	CcSEcCtD
Raloxifene—Angiopathy—Epirubicin—urinary bladder cancer	0.000109	0.00109	CcSEcCtD
Raloxifene—Urethral disorder—Doxorubicin—urinary bladder cancer	0.000109	0.00109	CcSEcCtD
Raloxifene—Nausea—Gemcitabine—urinary bladder cancer	0.000106	0.00105	CcSEcCtD
Raloxifene—Vomiting—Cisplatin—urinary bladder cancer	0.000106	0.00105	CcSEcCtD
Raloxifene—Rash—Cisplatin—urinary bladder cancer	0.000105	0.00104	CcSEcCtD
Raloxifene—Dermatitis—Cisplatin—urinary bladder cancer	0.000105	0.00104	CcSEcCtD
Raloxifene—Diarrhoea—Etoposide—urinary bladder cancer	0.000104	0.00104	CcSEcCtD
Raloxifene—Nausea—Fluorouracil—urinary bladder cancer	0.000104	0.00104	CcSEcCtD
Raloxifene—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.000103	0.00103	CcSEcCtD
Raloxifene—Flushing—Doxorubicin—urinary bladder cancer	0.000103	0.00103	CcSEcCtD
Raloxifene—Flatulence—Epirubicin—urinary bladder cancer	0.000103	0.00103	CcSEcCtD
Raloxifene—Angiopathy—Doxorubicin—urinary bladder cancer	0.000101	0.001	CcSEcCtD
Raloxifene—Dizziness—Etoposide—urinary bladder cancer	0.000101	0.001	CcSEcCtD
Raloxifene—Muscle spasms—Epirubicin—urinary bladder cancer	0.0001	0.001	CcSEcCtD
Raloxifene—Vertigo—Methotrexate—urinary bladder cancer	0.0001	0.001	CcSEcCtD
Raloxifene—Nausea—Cisplatin—urinary bladder cancer	9.87e-05	0.000983	CcSEcCtD
Raloxifene—Cough—Methotrexate—urinary bladder cancer	9.75e-05	0.000971	CcSEcCtD
Raloxifene—Vomiting—Etoposide—urinary bladder cancer	9.68e-05	0.000964	CcSEcCtD
Raloxifene—Rash—Etoposide—urinary bladder cancer	9.59e-05	0.000956	CcSEcCtD
Raloxifene—Dermatitis—Etoposide—urinary bladder cancer	9.59e-05	0.000955	CcSEcCtD
Raloxifene—Headache—Etoposide—urinary bladder cancer	9.53e-05	0.00095	CcSEcCtD
Raloxifene—Flatulence—Doxorubicin—urinary bladder cancer	9.53e-05	0.00095	CcSEcCtD
Raloxifene—Myalgia—Methotrexate—urinary bladder cancer	9.51e-05	0.000947	CcSEcCtD
Raloxifene—Arthralgia—Methotrexate—urinary bladder cancer	9.51e-05	0.000947	CcSEcCtD
Raloxifene—Chest pain—Methotrexate—urinary bladder cancer	9.51e-05	0.000947	CcSEcCtD
Raloxifene—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	9.44e-05	0.000941	CcSEcCtD
Raloxifene—Vertigo—Epirubicin—urinary bladder cancer	9.39e-05	0.000936	CcSEcCtD
Raloxifene—Syncope—Epirubicin—urinary bladder cancer	9.37e-05	0.000934	CcSEcCtD
Raloxifene—Muscle spasms—Doxorubicin—urinary bladder cancer	9.3e-05	0.000926	CcSEcCtD
Raloxifene—Loss of consciousness—Epirubicin—urinary bladder cancer	9.19e-05	0.000915	CcSEcCtD
Raloxifene—Cough—Epirubicin—urinary bladder cancer	9.12e-05	0.000909	CcSEcCtD
Raloxifene—Infection—Methotrexate—urinary bladder cancer	9.06e-05	0.000902	CcSEcCtD
Raloxifene—Nausea—Etoposide—urinary bladder cancer	9.04e-05	0.000901	CcSEcCtD
Raloxifene—Nervous system disorder—Methotrexate—urinary bladder cancer	8.94e-05	0.000891	CcSEcCtD
Raloxifene—Thrombocytopenia—Methotrexate—urinary bladder cancer	8.92e-05	0.000889	CcSEcCtD
Raloxifene—Arthralgia—Epirubicin—urinary bladder cancer	8.9e-05	0.000887	CcSEcCtD
Raloxifene—Myalgia—Epirubicin—urinary bladder cancer	8.9e-05	0.000887	CcSEcCtD
Raloxifene—Chest pain—Epirubicin—urinary bladder cancer	8.9e-05	0.000887	CcSEcCtD
Raloxifene—Skin disorder—Methotrexate—urinary bladder cancer	8.85e-05	0.000882	CcSEcCtD
Raloxifene—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	8.84e-05	0.000881	CcSEcCtD
Raloxifene—Hyperhidrosis—Methotrexate—urinary bladder cancer	8.81e-05	0.000878	CcSEcCtD
Raloxifene—Vertigo—Doxorubicin—urinary bladder cancer	8.69e-05	0.000866	CcSEcCtD
Raloxifene—Syncope—Doxorubicin—urinary bladder cancer	8.67e-05	0.000864	CcSEcCtD
Raloxifene—Loss of consciousness—Doxorubicin—urinary bladder cancer	8.5e-05	0.000847	CcSEcCtD
Raloxifene—Infection—Epirubicin—urinary bladder cancer	8.47e-05	0.000844	CcSEcCtD
Raloxifene—Cough—Doxorubicin—urinary bladder cancer	8.44e-05	0.000841	CcSEcCtD
Raloxifene—Shock—Epirubicin—urinary bladder cancer	8.39e-05	0.000836	CcSEcCtD
Raloxifene—Nervous system disorder—Epirubicin—urinary bladder cancer	8.37e-05	0.000834	CcSEcCtD
Raloxifene—Thrombocytopenia—Epirubicin—urinary bladder cancer	8.35e-05	0.000832	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	8.3e-05	0.000827	CcSEcCtD
Raloxifene—Skin disorder—Epirubicin—urinary bladder cancer	8.29e-05	0.000826	CcSEcCtD
Raloxifene—Hyperhidrosis—Epirubicin—urinary bladder cancer	8.25e-05	0.000822	CcSEcCtD
Raloxifene—Insomnia—Methotrexate—urinary bladder cancer	8.24e-05	0.000821	CcSEcCtD
Raloxifene—Arthralgia—Doxorubicin—urinary bladder cancer	8.23e-05	0.00082	CcSEcCtD
Raloxifene—Chest pain—Doxorubicin—urinary bladder cancer	8.23e-05	0.00082	CcSEcCtD
Raloxifene—Myalgia—Doxorubicin—urinary bladder cancer	8.23e-05	0.00082	CcSEcCtD
Raloxifene—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	8.18e-05	0.000815	CcSEcCtD
Raloxifene—Dyspepsia—Methotrexate—urinary bladder cancer	8.02e-05	0.000799	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	7.87e-05	0.000784	CcSEcCtD
Raloxifene—Infection—Doxorubicin—urinary bladder cancer	7.84e-05	0.000781	CcSEcCtD
Raloxifene—Pain—Methotrexate—urinary bladder cancer	7.79e-05	0.000777	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	7.77e-05	0.000774	CcSEcCtD
Raloxifene—Shock—Doxorubicin—urinary bladder cancer	7.77e-05	0.000774	CcSEcCtD
Raloxifene—Nervous system disorder—Doxorubicin—urinary bladder cancer	7.74e-05	0.000771	CcSEcCtD
Raloxifene—Thrombocytopenia—Doxorubicin—urinary bladder cancer	7.73e-05	0.00077	CcSEcCtD
Raloxifene—Insomnia—Epirubicin—urinary bladder cancer	7.72e-05	0.000769	CcSEcCtD
Raloxifene—Skin disorder—Doxorubicin—urinary bladder cancer	7.67e-05	0.000764	CcSEcCtD
Raloxifene—Hyperhidrosis—Doxorubicin—urinary bladder cancer	7.63e-05	0.00076	CcSEcCtD
Raloxifene—Dyspepsia—Epirubicin—urinary bladder cancer	7.51e-05	0.000748	CcSEcCtD
Raloxifene—Gastrointestinal pain—Methotrexate—urinary bladder cancer	7.45e-05	0.000743	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	7.36e-05	0.000734	CcSEcCtD
Raloxifene—Pain—Epirubicin—urinary bladder cancer	7.29e-05	0.000727	CcSEcCtD
Raloxifene—Body temperature increased—Methotrexate—urinary bladder cancer	7.21e-05	0.000718	CcSEcCtD
Raloxifene—Abdominal pain—Methotrexate—urinary bladder cancer	7.21e-05	0.000718	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	7.19e-05	0.000717	CcSEcCtD
Raloxifene—Insomnia—Doxorubicin—urinary bladder cancer	7.14e-05	0.000711	CcSEcCtD
Raloxifene—Gastrointestinal pain—Epirubicin—urinary bladder cancer	6.98e-05	0.000695	CcSEcCtD
Raloxifene—Dyspepsia—Doxorubicin—urinary bladder cancer	6.95e-05	0.000692	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	6.81e-05	0.000679	CcSEcCtD
Raloxifene—Pain—Doxorubicin—urinary bladder cancer	6.75e-05	0.000673	CcSEcCtD
Raloxifene—Body temperature increased—Epirubicin—urinary bladder cancer	6.74e-05	0.000672	CcSEcCtD
Raloxifene—Abdominal pain—Epirubicin—urinary bladder cancer	6.74e-05	0.000672	CcSEcCtD
Raloxifene—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	6.45e-05	0.000643	CcSEcCtD
Raloxifene—Abdominal pain—Doxorubicin—urinary bladder cancer	6.24e-05	0.000622	CcSEcCtD
Raloxifene—Body temperature increased—Doxorubicin—urinary bladder cancer	6.24e-05	0.000622	CcSEcCtD
Raloxifene—Diarrhoea—Methotrexate—urinary bladder cancer	6.24e-05	0.000621	CcSEcCtD
Raloxifene—Dizziness—Methotrexate—urinary bladder cancer	6.03e-05	0.000601	CcSEcCtD
Raloxifene—Diarrhoea—Epirubicin—urinary bladder cancer	5.84e-05	0.000582	CcSEcCtD
Raloxifene—Vomiting—Methotrexate—urinary bladder cancer	5.8e-05	0.000577	CcSEcCtD
Raloxifene—Rash—Methotrexate—urinary bladder cancer	5.75e-05	0.000573	CcSEcCtD
Raloxifene—Dermatitis—Methotrexate—urinary bladder cancer	5.74e-05	0.000572	CcSEcCtD
Raloxifene—Headache—Methotrexate—urinary bladder cancer	5.71e-05	0.000569	CcSEcCtD
Raloxifene—Dizziness—Epirubicin—urinary bladder cancer	5.64e-05	0.000562	CcSEcCtD
Raloxifene—Vomiting—Epirubicin—urinary bladder cancer	5.42e-05	0.00054	CcSEcCtD
Raloxifene—Nausea—Methotrexate—urinary bladder cancer	5.41e-05	0.000539	CcSEcCtD
Raloxifene—Diarrhoea—Doxorubicin—urinary bladder cancer	5.4e-05	0.000538	CcSEcCtD
Raloxifene—Rash—Epirubicin—urinary bladder cancer	5.38e-05	0.000536	CcSEcCtD
Raloxifene—Dermatitis—Epirubicin—urinary bladder cancer	5.37e-05	0.000535	CcSEcCtD
Raloxifene—Headache—Epirubicin—urinary bladder cancer	5.34e-05	0.000532	CcSEcCtD
Raloxifene—Dizziness—Doxorubicin—urinary bladder cancer	5.22e-05	0.00052	CcSEcCtD
Raloxifene—Nausea—Epirubicin—urinary bladder cancer	5.07e-05	0.000505	CcSEcCtD
Raloxifene—Vomiting—Doxorubicin—urinary bladder cancer	5.02e-05	0.0005	CcSEcCtD
Raloxifene—Rash—Doxorubicin—urinary bladder cancer	4.98e-05	0.000496	CcSEcCtD
Raloxifene—Dermatitis—Doxorubicin—urinary bladder cancer	4.97e-05	0.000495	CcSEcCtD
Raloxifene—Headache—Doxorubicin—urinary bladder cancer	4.94e-05	0.000493	CcSEcCtD
Raloxifene—Nausea—Doxorubicin—urinary bladder cancer	4.69e-05	0.000467	CcSEcCtD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	2.51e-05	0.000448	CbGpPWpGaD
Raloxifene—EBP—Metabolism—PTGS2—urinary bladder cancer	2.5e-05	0.000446	CbGpPWpGaD
Raloxifene—ESR1—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	2.49e-05	0.000446	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—TYMS—urinary bladder cancer	2.48e-05	0.000443	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—CYP4B1—urinary bladder cancer	2.48e-05	0.000443	CbGpPWpGaD
Raloxifene—ESR1—Integrated Breast Cancer Pathway—TP53—urinary bladder cancer	2.47e-05	0.000442	CbGpPWpGaD
Raloxifene—ESR2—Generic Transcription Pathway—MYC—urinary bladder cancer	2.46e-05	0.000439	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—GSTM1—urinary bladder cancer	2.45e-05	0.000438	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—NCOR1—urinary bladder cancer	2.45e-05	0.000438	CbGpPWpGaD
Raloxifene—ESR1—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	2.44e-05	0.000436	CbGpPWpGaD
Raloxifene—AOX1—Disease—FGFR3—urinary bladder cancer	2.37e-05	0.000423	CbGpPWpGaD
Raloxifene—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	2.35e-05	0.000421	CbGpPWpGaD
Raloxifene—ESR1—Signaling by ERBB4—HRAS—urinary bladder cancer	2.35e-05	0.00042	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—GPX1—urinary bladder cancer	2.35e-05	0.000419	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—SLC19A1—urinary bladder cancer	2.34e-05	0.000418	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—UGT2B7—urinary bladder cancer	2.33e-05	0.000416	CbGpPWpGaD
Raloxifene—ESR1—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	2.32e-05	0.000415	CbGpPWpGaD
Raloxifene—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	2.32e-05	0.000415	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—ERCC2—urinary bladder cancer	2.31e-05	0.000412	CbGpPWpGaD
Raloxifene—ESR1—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	2.3e-05	0.000412	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—PRSS3—urinary bladder cancer	2.28e-05	0.000407	CbGpPWpGaD
Raloxifene—ESR2—Gene Expression—ESR1—urinary bladder cancer	2.27e-05	0.000406	CbGpPWpGaD
Raloxifene—HTR6—GPCR ligand binding—CXCL8—urinary bladder cancer	2.25e-05	0.000402	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—RRM2—urinary bladder cancer	2.22e-05	0.000396	CbGpPWpGaD
Raloxifene—EBP—Metabolism—PTEN—urinary bladder cancer	2.18e-05	0.000389	CbGpPWpGaD
Raloxifene—ESR1—Generic Transcription Pathway—PPARG—urinary bladder cancer	2.17e-05	0.000388	CbGpPWpGaD
Raloxifene—ESR1—Gene Expression—SMC1A—urinary bladder cancer	2.17e-05	0.000388	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—MTHFR—urinary bladder cancer	2.17e-05	0.000387	CbGpPWpGaD
Raloxifene—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	2.16e-05	0.000387	CbGpPWpGaD
Raloxifene—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—urinary bladder cancer	2.14e-05	0.000382	CbGpPWpGaD
Raloxifene—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	2.13e-05	0.000381	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—GLI1—urinary bladder cancer	2.13e-05	0.00038	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—CYP4B1—urinary bladder cancer	2.1e-05	0.000375	CbGpPWpGaD
Raloxifene—ESR1—Generic Transcription Pathway—CREBBP—urinary bladder cancer	2.09e-05	0.000373	CbGpPWpGaD
Raloxifene—ESR2—Gene Expression—PPARG—urinary bladder cancer	2.08e-05	0.000371	CbGpPWpGaD
Raloxifene—EBP—Metabolism—EP300—urinary bladder cancer	2.08e-05	0.000371	CbGpPWpGaD
Raloxifene—HTR2B—GPCR ligand binding—CXCL8—urinary bladder cancer	2.06e-05	0.000367	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—ENO2—urinary bladder cancer	2.05e-05	0.000367	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—HPGDS—urinary bladder cancer	2.05e-05	0.000367	CbGpPWpGaD
Raloxifene—ESR1—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	2.05e-05	0.000366	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.04e-05	0.000364	CbGpPWpGaD
Raloxifene—AOX1—Disease—CREBBP—urinary bladder cancer	2.02e-05	0.00036	CbGpPWpGaD
Raloxifene—ESR2—Gene Expression—CREBBP—urinary bladder cancer	1.99e-05	0.000356	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—GSTT1—urinary bladder cancer	1.99e-05	0.000356	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—SLC19A1—urinary bladder cancer	1.98e-05	0.000354	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.96e-05	0.00035	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—PRSS3—urinary bladder cancer	1.93e-05	0.000345	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—RBX1—urinary bladder cancer	1.92e-05	0.000342	CbGpPWpGaD
Raloxifene—ESR1—Gene Expression—ESR2—urinary bladder cancer	1.89e-05	0.000338	CbGpPWpGaD
Raloxifene—AOX1—Disease—RHOA—urinary bladder cancer	1.82e-05	0.000326	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—TYMP—urinary bladder cancer	1.82e-05	0.000326	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—TSC1—urinary bladder cancer	1.8e-05	0.000322	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—PPARG—urinary bladder cancer	1.76e-05	0.000314	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—RBX1—urinary bladder cancer	1.75e-05	0.000312	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—JAG1—urinary bladder cancer	1.71e-05	0.000306	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—CREBBP—urinary bladder cancer	1.69e-05	0.000302	CbGpPWpGaD
Raloxifene—AOX1—Disease—ERBB2—urinary bladder cancer	1.69e-05	0.000302	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—NQO1—urinary bladder cancer	1.65e-05	0.000296	CbGpPWpGaD
Raloxifene—AOX1—Disease—PTGS2—urinary bladder cancer	1.65e-05	0.000295	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—NAT2—urinary bladder cancer	1.65e-05	0.000295	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—TSC1—urinary bladder cancer	1.64e-05	0.000294	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.61e-05	0.000287	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—JAG1—urinary bladder cancer	1.57e-05	0.00028	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	1.55e-05	0.000277	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—TYMP—urinary bladder cancer	1.54e-05	0.000276	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	1.48e-05	0.000265	CbGpPWpGaD
Raloxifene—ESR1—Gene Expression—NCOR1—urinary bladder cancer	1.46e-05	0.000261	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—RBX1—urinary bladder cancer	1.46e-05	0.00026	CbGpPWpGaD
Raloxifene—HTR6—GPCR downstream signaling—RHOA—urinary bladder cancer	1.45e-05	0.000259	CbGpPWpGaD
Raloxifene—AOX1—Disease—CDKN1A—urinary bladder cancer	1.44e-05	0.000258	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	1.44e-05	0.000258	CbGpPWpGaD
Raloxifene—AOX1—Disease—PTEN—urinary bladder cancer	1.44e-05	0.000257	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—RRM2—urinary bladder cancer	1.42e-05	0.000254	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.4e-05	0.00025	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—NAT2—urinary bladder cancer	1.4e-05	0.000249	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—S100B—urinary bladder cancer	1.39e-05	0.000248	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—PTGS2—urinary bladder cancer	1.38e-05	0.000247	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—GSTP1—urinary bladder cancer	1.38e-05	0.000246	CbGpPWpGaD
Raloxifene—AOX1—Disease—EP300—urinary bladder cancer	1.37e-05	0.000245	CbGpPWpGaD
Raloxifene—ESR1—Gene Expression—ERCC2—urinary bladder cancer	1.37e-05	0.000245	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—TSC1—urinary bladder cancer	1.37e-05	0.000245	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—NAT1—urinary bladder cancer	1.37e-05	0.000244	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	1.37e-05	0.000244	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.34e-05	0.000238	CbGpPWpGaD
Raloxifene—AOX1—Disease—SRC—urinary bladder cancer	1.34e-05	0.000238	CbGpPWpGaD
Raloxifene—HTR2B—GPCR downstream signaling—RHOA—urinary bladder cancer	1.32e-05	0.000236	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—ENO2—urinary bladder cancer	1.32e-05	0.000235	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—HPGDS—urinary bladder cancer	1.32e-05	0.000235	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—RHOA—urinary bladder cancer	1.32e-05	0.000235	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—JAG1—urinary bladder cancer	1.3e-05	0.000233	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—TYMS—urinary bladder cancer	1.28e-05	0.000229	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—GSTT1—urinary bladder cancer	1.28e-05	0.000228	CbGpPWpGaD
Raloxifene—HTR6—GPCR downstream signaling—CXCL8—urinary bladder cancer	1.27e-05	0.000227	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—NCOR1—urinary bladder cancer	1.27e-05	0.000226	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—GSTM1—urinary bladder cancer	1.27e-05	0.000226	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—S100B—urinary bladder cancer	1.27e-05	0.000226	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	1.25e-05	0.000223	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—NCOR1—urinary bladder cancer	1.25e-05	0.000223	CbGpPWpGaD
Raloxifene—ESR1—Generic Transcription Pathway—MYC—urinary bladder cancer	1.24e-05	0.000221	CbGpPWpGaD
Raloxifene—HTR6—GPCR downstream signaling—IL2—urinary bladder cancer	1.22e-05	0.000217	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—GPX1—urinary bladder cancer	1.21e-05	0.000217	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—PTEN—urinary bladder cancer	1.21e-05	0.000215	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—RRM2—urinary bladder cancer	1.21e-05	0.000215	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—RHOA—urinary bladder cancer	1.2e-05	0.000215	CbGpPWpGaD
Raloxifene—AOX1—Disease—MYC—urinary bladder cancer	1.2e-05	0.000214	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—ERCC2—urinary bladder cancer	1.19e-05	0.000213	CbGpPWpGaD
Raloxifene—ESR2—Gene Expression—MYC—urinary bladder cancer	1.18e-05	0.000211	CbGpPWpGaD
Raloxifene—AOX1—Disease—EGFR—urinary bladder cancer	1.17e-05	0.000209	CbGpPWpGaD
Raloxifene—HTR2B—GPCR downstream signaling—CXCL8—urinary bladder cancer	1.16e-05	0.000207	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—CXCL8—urinary bladder cancer	1.16e-05	0.000206	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—EP300—urinary bladder cancer	1.15e-05	0.000205	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—NCOR1—urinary bladder cancer	1.14e-05	0.000204	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	1.13e-05	0.000201	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—MTHFR—urinary bladder cancer	1.12e-05	0.0002	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—HPGDS—urinary bladder cancer	1.12e-05	0.000199	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—ENO2—urinary bladder cancer	1.12e-05	0.000199	CbGpPWpGaD
Raloxifene—HTR2B—GPCR downstream signaling—IL2—urinary bladder cancer	1.11e-05	0.000198	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.11e-05	0.000198	CbGpPWpGaD
Raloxifene—AOX1—Disease—KRAS—urinary bladder cancer	1.11e-05	0.000197	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—IL2—urinary bladder cancer	1.1e-05	0.000197	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—TERT—urinary bladder cancer	1.1e-05	0.000197	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—GSTT1—urinary bladder cancer	1.08e-05	0.000193	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.07e-05	0.00019	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	1.06e-05	0.00019	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—NQO1—urinary bladder cancer	1.06e-05	0.00019	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—S100B—urinary bladder cancer	1.06e-05	0.000189	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—CXCL8—urinary bladder cancer	1.05e-05	0.000188	CbGpPWpGaD
Raloxifene—ESR1—Gene Expression—PPARG—urinary bladder cancer	1.05e-05	0.000187	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	1.04e-05	0.000185	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—FGFR3—urinary bladder cancer	1.01e-05	0.00018	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—IL2—urinary bladder cancer	1.01e-05	0.00018	CbGpPWpGaD
Raloxifene—ESR1—Gene Expression—CREBBP—urinary bladder cancer	1.01e-05	0.00018	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—TERT—urinary bladder cancer	1e-05	0.000179	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—ESR1—urinary bladder cancer	9.81e-06	0.000175	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—NCOR1—urinary bladder cancer	9.49e-06	0.00017	CbGpPWpGaD
Raloxifene—AOX1—Disease—HRAS—urinary bladder cancer	9.4e-06	0.000168	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—FGFR3—urinary bladder cancer	9.22e-06	0.000165	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—PPARG—urinary bladder cancer	9.09e-06	0.000162	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—NQO1—urinary bladder cancer	9e-06	0.000161	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—ESR1—urinary bladder cancer	8.95e-06	0.00016	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—GSTP1—urinary bladder cancer	8.86e-06	0.000158	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—CREBBP—urinary bladder cancer	8.73e-06	0.000156	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	8.73e-06	0.000156	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—CREBBP—urinary bladder cancer	8.6e-06	0.000154	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—IGF1—urinary bladder cancer	8.49e-06	0.000152	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—EGFR—urinary bladder cancer	8.45e-06	0.000151	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—TERT—urinary bladder cancer	8.37e-06	0.000149	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—TYMP—urinary bladder cancer	8.29e-06	0.000148	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—TYMS—urinary bladder cancer	8.24e-06	0.000147	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—NCOR1—urinary bladder cancer	8.14e-06	0.000145	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—GSTM1—urinary bladder cancer	8.14e-06	0.000145	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—KRAS—urinary bladder cancer	7.98e-06	0.000143	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—CREBBP—urinary bladder cancer	7.85e-06	0.00014	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—GPX1—urinary bladder cancer	7.8e-06	0.000139	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—RHOA—urinary bladder cancer	7.78e-06	0.000139	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—IGF1—urinary bladder cancer	7.75e-06	0.000138	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—EGFR—urinary bladder cancer	7.71e-06	0.000138	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—FGFR3—urinary bladder cancer	7.68e-06	0.000137	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—ERCC2—urinary bladder cancer	7.66e-06	0.000137	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	7.61e-06	0.000136	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—GSTP1—urinary bladder cancer	7.5e-06	0.000134	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—NAT2—urinary bladder cancer	7.49e-06	0.000134	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—KRAS—urinary bladder cancer	7.28e-06	0.00013	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	7.26e-06	0.00013	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—ERBB2—urinary bladder cancer	7.2e-06	0.000129	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—MTHFR—urinary bladder cancer	7.2e-06	0.000129	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—PTGS2—urinary bladder cancer	7.15e-06	0.000128	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—RHOA—urinary bladder cancer	7.1e-06	0.000127	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—TYMS—urinary bladder cancer	6.98e-06	0.000125	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—GSTM1—urinary bladder cancer	6.9e-06	0.000123	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—NCOR1—urinary bladder cancer	6.9e-06	0.000123	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—CXCL8—urinary bladder cancer	6.83e-06	0.000122	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—HRAS—urinary bladder cancer	6.78e-06	0.000121	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—GPX1—urinary bladder cancer	6.6e-06	0.000118	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—ERBB2—urinary bladder cancer	6.57e-06	0.000117	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—CREBBP—urinary bladder cancer	6.54e-06	0.000117	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—IL2—urinary bladder cancer	6.52e-06	0.000117	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—ERCC2—urinary bladder cancer	6.48e-06	0.000116	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—RRM2—urinary bladder cancer	6.47e-06	0.000116	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—IGF1—urinary bladder cancer	6.45e-06	0.000115	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—CCND1—urinary bladder cancer	6.36e-06	0.000114	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—PTEN—urinary bladder cancer	6.24e-06	0.000111	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—CXCL8—urinary bladder cancer	6.23e-06	0.000111	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—HRAS—urinary bladder cancer	6.19e-06	0.000111	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—MMP9—urinary bladder cancer	6.17e-06	0.00011	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—CDKN1A—urinary bladder cancer	6.15e-06	0.00011	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—PTEN—urinary bladder cancer	6.14e-06	0.00011	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—MTHFR—urinary bladder cancer	6.09e-06	0.000109	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	5.99e-06	0.000107	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—ENO2—urinary bladder cancer	5.99e-06	0.000107	CbGpPWpGaD
Raloxifene—ESR1—Gene Expression—MYC—urinary bladder cancer	5.97e-06	0.000107	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—IL2—urinary bladder cancer	5.96e-06	0.000106	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—EP300—urinary bladder cancer	5.95e-06	0.000106	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—RHOA—urinary bladder cancer	5.91e-06	0.000106	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—EP300—urinary bladder cancer	5.85e-06	0.000105	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—PPARG—urinary bladder cancer	5.84e-06	0.000104	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	5.81e-06	0.000104	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—CCND1—urinary bladder cancer	5.81e-06	0.000104	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—SRC—urinary bladder cancer	5.69e-06	0.000102	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—MMP9—urinary bladder cancer	5.64e-06	0.000101	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—CDKN1A—urinary bladder cancer	5.62e-06	0.0001	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—CREBBP—urinary bladder cancer	5.61e-06	0.0001	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—PTEN—urinary bladder cancer	5.6e-06	0.0001	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—ERBB2—urinary bladder cancer	5.47e-06	9.78e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—EP300—urinary bladder cancer	5.34e-06	9.54e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—SRC—urinary bladder cancer	5.2e-06	9.28e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—CXCL8—urinary bladder cancer	5.19e-06	9.27e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—MYC—urinary bladder cancer	5.1e-06	9.11e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—EGFR—urinary bladder cancer	4.99e-06	8.91e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—IL2—urinary bladder cancer	4.96e-06	8.86e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—PPARG—urinary bladder cancer	4.94e-06	8.83e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—CCND1—urinary bladder cancer	4.84e-06	8.64e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—NQO1—urinary bladder cancer	4.83e-06	8.62e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—CREBBP—urinary bladder cancer	4.75e-06	8.48e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—KRAS—urinary bladder cancer	4.71e-06	8.42e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—MMP9—urinary bladder cancer	4.69e-06	8.39e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—CDKN1A—urinary bladder cancer	4.68e-06	8.36e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—PTEN—urinary bladder cancer	4.67e-06	8.34e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—MYC—urinary bladder cancer	4.66e-06	8.32e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—PTGS2—urinary bladder cancer	4.59e-06	8.2e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—EGFR—urinary bladder cancer	4.55e-06	8.13e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—EP300—urinary bladder cancer	4.45e-06	7.95e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—SRC—urinary bladder cancer	4.33e-06	7.73e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—KRAS—urinary bladder cancer	4.3e-06	7.68e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—TP53—urinary bladder cancer	4.19e-06	7.48e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	4.03e-06	7.19e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—HRAS—urinary bladder cancer	4.01e-06	7.16e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—PTEN—urinary bladder cancer	4e-06	7.15e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—PTGS2—urinary bladder cancer	3.89e-06	6.94e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—MYC—urinary bladder cancer	3.88e-06	6.93e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—TP53—urinary bladder cancer	3.82e-06	6.83e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—EP300—urinary bladder cancer	3.82e-06	6.82e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—EGFR—urinary bladder cancer	3.79e-06	6.78e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—TYMS—urinary bladder cancer	3.74e-06	6.69e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	3.7e-06	6.61e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	3.7e-06	6.61e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—HRAS—urinary bladder cancer	3.66e-06	6.53e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—KRAS—urinary bladder cancer	3.58e-06	6.4e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—GPX1—urinary bladder cancer	3.54e-06	6.33e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	3.48e-06	6.21e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—PTEN—urinary bladder cancer	3.39e-06	6.05e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	3.27e-06	5.84e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—EP300—urinary bladder cancer	3.23e-06	5.77e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—TP53—urinary bladder cancer	3.19e-06	5.69e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—HRAS—urinary bladder cancer	3.05e-06	5.44e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—PPARG—urinary bladder cancer	2.65e-06	4.74e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	2.55e-06	4.55e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	2.09e-06	3.73e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—PTEN—urinary bladder cancer	1.82e-06	3.25e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—EP300—urinary bladder cancer	1.74e-06	3.1e-05	CbGpPWpGaD
